$TOI
Oncology Institute, Inc. Stock $toi

$toi Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022005868 Filed on March 11, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$52.30M	$203.0M	$0.00
YoY Change		8.26%
Cost Of Revenue	$43.97M	$162.2M	$38.12M
YoY Change	15.35%	7.65%
Gross Profit	$8.333M	$40.85M	$10.84M
YoY Change	-23.13%	10.76%
Gross Profit Margin	15.93%	20.12%
Selling, General & Admin	$48.25M	$83.37M	$203.1K
YoY Change	23659.06%	98.97%
% of Gross Profit	578.95%	204.09%	1.87%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$919.4K	$3.341M	$790.0K
YoY Change	16.38%	5.13%
% of Gross Profit	11.03%	8.18%	7.29%
Operating Expenses	$49.16M	$83.37M	$203.1K
YoY Change	24111.84%	98.97%
Operating Profit	-$40.83M	-$45.86M	$10.64M
YoY Change	-483.86%	459.45%
Interest Expense	-$60.11K	$320.0K	-$7.524M
YoY Change	-99.2%	-7.78%
% of Operating Profit			-70.74%
Other Income/Expense, Net	$28.50M	$34.26M	-$315.1K
YoY Change	-9144.52%	-617.68%
Pretax Income	-$12.62M	-$11.60M	-$8.043M
YoY Change	56.96%	-21.71%
Income Tax	-$2.467M	-$671.0K	-$1.140K
% Of Pretax Income
Net Earnings	-$10.16M	-$10.93M	-$8.041M
YoY Change	26.3%	-23.7%
Net Earnings / Revenue	-19.42%	-5.38%
Basic Earnings Per Share		-$0.16
Diluted Earnings Per Share	-$138.7K	-$0.16	-$285.6K
COMMON SHARES
Basic Shares Outstanding		66.23M shares
Diluted Shares Outstanding		66.23M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$115.2M	$114.3M	$917.0K
YoY Change	12460.01%	1805.62%
Cash & Equivalents	$115.2M		$5.998M
Short-Term Investments
Other Short-Term Assets	$11.20M	$12.08M	$152.5K
YoY Change	7245.71%	472.55%
Inventory	$6.438M	$6.438M	$4.354M
Prepaid Expenses	$11.20M		$2.109M
Receivables	$20.01M	$20.01M	$17.15M
Other Receivables	$1.237M	$1.237M	$113.0K
Total Short-Term Assets	$154.1M	$154.1M	$29.72M
YoY Change	418.36%	418.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.192M	$4.192M	$2.104M
YoY Change	99.24%	99.24%
Goodwill	$26.63M		$14.23M
YoY Change	87.15%
Intangibles	$18.25M		$19.52M
YoY Change	-6.51%
Long-Term Investments			$230.3M
YoY Change
Other Assets	$320.0K	$320.0K	$122.0K
YoY Change	162.3%	162.3%
Total Long-Term Assets	$49.38M	$49.38M	$35.97M
YoY Change	37.29%	37.29%
TOTAL ASSETS
Total Short-Term Assets	$154.1M	$154.1M	$29.72M
Total Long-Term Assets	$49.38M	$49.38M	$35.97M
Total Assets	$203.4M	$203.4M	$65.69M
YoY Change	209.7%	209.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.56M	$15.56M	$12.64M
YoY Change	23.06%	23.06%
Accrued Expenses	$13.92M	$10.69M	$9.452M
YoY Change	47.31%	151.01%
Deferred Revenue	$262.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$183.0K	$183.0K	$5.368M
YoY Change	-96.59%	-96.59%
Total Short-Term Liabilities	$29.80M	$29.80M	$28.61M
YoY Change	4.16%	4.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$6.561M
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$6.900M	$69.11M	$807.0K
YoY Change	755.02%	8463.94%
Total Long-Term Liabilities	$6.900M	$69.11M	$7.368M
YoY Change	-6.35%	837.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.80M	$29.80M	$28.61M
Total Long-Term Liabilities	$6.900M	$69.11M	$7.368M
Total Liabilities	$99.28M	$99.28M	$37.59M
YoY Change	164.13%	164.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$63.23M		-$52.31M
YoY Change	20.89%
Common Stock	$7.000K		$6.000K
YoY Change	16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$104.2M	$104.2M	$28.10M
YoY Change
Total Liabilities & Shareholders Equity	$203.4M	$203.4M	$65.69M
YoY Change	209.7%	209.7%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$10.16M	-$10.93M	-$8.041M
YoY Change	26.3%	-23.7%
Depreciation, Depletion And Amortization	$919.4K	$3.341M	$790.0K
YoY Change	16.38%	5.13%
Cash From Operating Activities	-$23.34M	-$32.68M	-$81.59K
YoY Change	28500.67%	-6533.07%
INVESTING ACTIVITIES
Capital Expenditures	-$871.4K	$2.847M	$350.0K
YoY Change	-348.96%	138.44%
Acquisitions		$9.107M
YoY Change		5971.33%
Other Investing Activities	-$8.280M	-$9.107M	$0.00
YoY Change		19.05%
Cash From Investing Activities	-$9.151M	-$12.15M	$0.00
YoY Change		37.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$7.219M
YoY Change		2469.04%
Cash From Financing Activities	136.1M	$154.0M	0.000
YoY Change		1195.51%
NET CHANGE
Cash From Operating Activities	-23.34M	-$32.68M	-81.59K
Cash From Investing Activities	-9.151M	-$12.15M	0.000
Cash From Financing Activities	136.1M	$154.0M	0.000
Net Change In Cash	103.6M	$109.2M	-81.59K
YoY Change	-127127.26%	2973.65%
FREE CASH FLOW
Cash From Operating Activities	-$23.34M	-$32.68M	-$81.59K
Capital Expenditures	-$871.4K	$2.847M	$350.0K
Free Cash Flow	-$22.46M	-$35.53M	-$431.6K
YoY Change	5104.92%	5078.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001799191
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1194000	USD
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39248
CY2021	dei	Entity Registrant Name EntityRegistrantName	The Oncology Institute, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-3562323
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	18000 Studebaker Rd, Suite 800
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Cerritos
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90703
CY2021	dei	City Area Code CityAreaCode	562
CY2021	dei	Local Phone Number LocalPhoneNumber	735-3226
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	179100000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73249046	shares
CY2021Q4	toi	Reverse Recapitalization Net ReverseRecapitalizationNet	762052000	USD
CY2021Q4	toi	Reverse Recapitalization Equity Consideration Value ReverseRecapitalizationEquityConsiderationValue	595468000	USD
CY2021Q4	toi	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	166584000	USD
CY2021	dei	Auditor Name AuditorName	BDO USA, LLP
CY2021	dei	Auditor Location AuditorLocation	Costa Mesa, California
CY2021	dei	Auditor Firm AuditorFirmId	243
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	875000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115174000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5998000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20007000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17146000	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1237000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	113000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	6438000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4354000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11200000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2109000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	154056000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	29720000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4192000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2104000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18245000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19516000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	26626000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	14227000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	320000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	122000	USD
CY2021Q4	us-gaap	Assets Assets	203439000	USD
CY2020Q4	us-gaap	Assets Assets	65689000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	183000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5368000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15559000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12643000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	132000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1144000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13924000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9452000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29798000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28607000	USD
CY2021Q4	toi	Derivative Warrant Liabilities Noncurrent DerivativeWarrantLiabilitiesNoncurrent	2193000	USD
CY2020Q4	toi	Derivative Warrant Liabilities Noncurrent DerivativeWarrantLiabilitiesNoncurrent	0	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	60018000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6561000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6900000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	807000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	371000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1613000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	99280000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	37588000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73249042	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	73249042	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	163510	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	163510	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167386000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80402000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63234000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52307000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	104159000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28101000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203439000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65689000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	203003000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	187515000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	83365000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41898000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3341000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3178000	USD
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	248861000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14815000	USD
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	195712000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-45858000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-8197000	USD
CY2021	us-gaap	Interest Expense InterestExpense	320000	USD
CY2020	us-gaap	Interest Expense InterestExpense	347000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3686000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	24891000	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4957000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1046000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6271000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	34260000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6618000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11598000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-671000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-493000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10927000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-14322000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66230606	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66230606	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59117723	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59117723	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	42222000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-14322000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	151000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28101000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10927000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46099000	USD
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	16351000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24535000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	104159000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10927000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-14322000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3341000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3178000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	53000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	60000	USD
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7500000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	24535000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	151000	USD
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	792000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3686000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	24891000	USD
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1242000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1344000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	4957000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-417000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4233000	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-60000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2195000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6763000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1842000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	465000	USD
CY2020	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-5000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	9091000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1386000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	198000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	25000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3084000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5210000	USD
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1012000	USD
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	655000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2916000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3758000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	809000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32680000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	508000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2847000	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	200000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9107000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	150000	USD
CY2021	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	USD
CY2020	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	7500000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12154000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8844000	USD
CY2021	toi	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	333946000	USD
CY2020	toi	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	0	USD
CY2021	toi	Payments For Reverse Recapitalization Transaction Costs PaymentsForReverseRecapitalizationTransactionCosts	33145000	USD
CY2020	toi	Payments For Reverse Recapitalization Transaction Costs PaymentsForReverseRecapitalizationTransactionCosts	0	USD
CY2021	toi	Payments As A Result Of Recapitalization Transaction PaymentsAsAResultOfRecapitalizationTransaction	167510000	USD
CY2020	toi	Payments As A Result Of Recapitalization Transaction PaymentsAsAResultOfRecapitalizationTransaction	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	12493000	USD
CY2021	toi	Proceeds From Financing Of Insurance Payments ProceedsFromFinancingOfInsurancePayments	8429000	USD
CY2020	toi	Proceeds From Financing Of Insurance Payments ProceedsFromFinancingOfInsurancePayments	0	USD
CY2021	toi	Payments For Financing Of Insurance Payments PaymentsForFinancingOfInsurancePayments	409000	USD
CY2020	toi	Payments For Financing Of Insurance Payments PaymentsForFinancingOfInsurancePayments	0	USD
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	50000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7219000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	281000	USD
CY2021	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	32000	USD
CY2020	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	31000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	343000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000	USD
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	20000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1727000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	207000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	504000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	154010000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11888000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	109176000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3552000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5998000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2446000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115174000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5998000	USD
CY2021	toi	Reclassification Of Public Warrant Derivative Liability Related To The Recapitalization Transaction Into Equity ReclassificationOfPublicWarrantDerivativeLiabilityRelatedToTheRecapitalizationTransactionIntoEquity	10580000	USD
CY2020	toi	Reclassification Of Public Warrant Derivative Liability Related To The Recapitalization Transaction Into Equity ReclassificationOfPublicWarrantDerivativeLiabilityRelatedToTheRecapitalizationTransactionIntoEquity	0	USD
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	1175000	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2021	toi	Deferred Consideration As Part Of Practice Acquisitions DeferredConsiderationAsPartOfPracticeAcquisitions	4468000	USD
CY2020	toi	Deferred Consideration As Part Of Practice Acquisitions DeferredConsiderationAsPartOfPracticeAcquisitions	0	USD
CY2021	toi	Interest And Principal Forgiven From Paycheck Protection Program Loan Cares Act InterestAndPrincipalForgivenFromPaycheckProtectionProgramLoanCaresAct	4957000	USD
CY2020	toi	Interest And Principal Forgiven From Paycheck Protection Program Loan Cares Act InterestAndPrincipalForgivenFromPaycheckProtectionProgramLoanCaresAct	0	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	275000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	227000	USD
CY2021	toi	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	3	subsidiary
CY2021	toi	Number Of Oncologists And Mid Level Professionals Within Three States Minimum NumberOfOncologistsAndMidLevelProfessionalsWithinThreeStatesMinimum	86	oncologist
CY2021	toi	Number Of Clinic Locations NumberOfClinicLocations	53	clinic
CY2021Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	4	state
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates under different assumptions or conditions. Significant items subject to such estimates and assumptions include judgements related to revenue recognition, estimated accounts receivable, useful lives and recoverability of long-lived and intangible assets, recoverability of goodwill, fair values of acquired assets and assumed liabilities in business combinations, fair value of intangible assets and goodwill, fair value of share-based compensation, fair value of liability classified instruments, and judgements related to deferred income taxes.</span></div>
CY2021	toi	Health Care Services Term HealthCareServicesTerm	P1M
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021	toi	Defined Contribution Plan Required Service Period DefinedContributionPlanRequiredServicePeriod	P2M
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2020	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	0.50
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	787000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1158000	USD
CY2021Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	63000	USD
CY2020Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	97000	USD
CY2021Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	96000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20007000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17146000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	48000	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	4233000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	465000	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	203003000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	187515000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	220000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	370000	USD
CY2020Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	128000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	6438000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4354000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	115174000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	5998000	USD
CY2021Q4	us-gaap	Accounts Receivable Fair Value Disclosure AccountsReceivableFairValueDisclosure	20007000	USD
CY2020Q4	us-gaap	Accounts Receivable Fair Value Disclosure AccountsReceivableFairValueDisclosure	17146000	USD
CY2021Q4	toi	Other Receivables Fair Value Disclosure OtherReceivablesFairValueDisclosure	1237000	USD
CY2020Q4	toi	Other Receivables Fair Value Disclosure OtherReceivablesFairValueDisclosure	113000	USD
CY2021Q4	us-gaap	Accounts Payable Fair Value Disclosure AccountsPayableFairValueDisclosure	15559000	USD
CY2020Q4	us-gaap	Accounts Payable Fair Value Disclosure AccountsPayableFairValueDisclosure	12643000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1984000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4192000	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1813000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13924000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2104000	USD
CY2021	us-gaap	Depreciation Depreciation	826000	USD
CY2020	us-gaap	Depreciation Depreciation	691000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3325000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4210000	USD
CY2021Q4	toi	Deferred Revenue And Refund Liabilities Current DeferredRevenueAndRefundLiabilitiesCurrent	592000	USD
CY2020Q4	toi	Deferred Revenue And Refund Liabilities Current DeferredRevenueAndRefundLiabilitiesCurrent	3379000	USD
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	5009000	USD
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	0	USD
CY2021Q4	toi	Business Combination Consideration Transferred Other Current BusinessCombinationConsiderationTransferredOtherCurrent	2359000	USD
CY2020Q4	toi	Business Combination Consideration Transferred Other Current BusinessCombinationConsiderationTransferredOtherCurrent	50000	USD
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	2639000	USD
CY2020	toi	Effective Income Tax Rate Reconciliation Transaction Costs Amount EffectiveIncomeTaxRateReconciliationTransactionCostsAmount	0	USD
CY2021	toi	Effective Income Tax Rate Reconciliation Fines And Penalties EffectiveIncomeTaxRateReconciliationFinesAndPenalties	28000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9452000	USD
CY2021Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	8020000	USD
CY2021Q4	us-gaap	Accrued Insurance Noncurrent AccruedInsuranceNoncurrent	3011000	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	4281000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	3680000	USD
CY2021Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	162000	USD
CY2020Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	163000	USD
CY2021Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	69000	USD
CY2020Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	38000	USD
CY2021Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	93000	USD
CY2020Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	125000	USD
CY2021Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	33000	USD
CY2020Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	31000	USD
CY2021Q4	us-gaap	Debt Current DebtCurrent	183000	USD
CY2020Q4	us-gaap	Debt Current DebtCurrent	5368000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6561000	USD
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	0	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	283000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	53000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	60000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	29000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-180000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-904000	USD
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-1084000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	750000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-338000	USD
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	413000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	570000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1242000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-671000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	822000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-919000	USD
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-97000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-425000	USD
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-396000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	851000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1344000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-493000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2436000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3111000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-241000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-982000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	11000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	0	USD
CY2021	toi	Effective Income Tax Rate Reconciliation Transaction Costs Amount EffectiveIncomeTaxRateReconciliationTransactionCostsAmount	349000	USD
CY2020	toi	Effective Income Tax Rate Reconciliation162m Analysis Amount EffectiveIncomeTaxRateReconciliation162mAnalysisAmount	0	USD
CY2020	toi	Effective Income Tax Rate Reconciliation Fines And Penalties EffectiveIncomeTaxRateReconciliationFinesAndPenalties	0	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-122000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	USD
CY2021	toi	Effective Income Tax Rate Reconciliation Warrant Expense Amount EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount	774000	USD
CY2020	toi	Effective Income Tax Rate Reconciliation Warrant Expense Amount EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount	0	USD
CY2021	toi	Effective Income Tax Rate Reconciliation Earnout Expense Amount EffectiveIncomeTaxRateReconciliationEarnoutExpenseAmount	5227000	USD
CY2020	toi	Effective Income Tax Rate Reconciliation Earnout Expense Amount EffectiveIncomeTaxRateReconciliationEarnoutExpenseAmount	0	USD
CY2021	toi	Effective Income Tax Rate Reconciliation Ppp Loan Forgiveness Amount EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessAmount	1058000	USD
CY2020	toi	Effective Income Tax Rate Reconciliation Ppp Loan Forgiveness Amount EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessAmount	0	USD
CY2021	toi	Effective Income Tax Rate Reconciliation162m Analysis Amount EffectiveIncomeTaxRateReconciliation162mAnalysisAmount	1717000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6941000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3597000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	141000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	3000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-671000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-493000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	173000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	108000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	606000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	770000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12686000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2529000	USD
CY2021Q4	toi	Deferred Tax Assets Management Fees DeferredTaxAssetsManagementFees	0	USD
CY2020Q4	toi	Deferred Tax Assets Management Fees DeferredTaxAssetsManagementFees	1828000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	1751000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	2086000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	77000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	182000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1088000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	69000	USD
CY2020Q4	toi	Deferred Tax Liabilities Management Fees DeferredTaxLiabilitiesManagementFees	1828000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16381000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7572000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14719000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5451000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1662000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2121000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	706000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	331000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1327000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1575000	USD
CY2021Q4	toi	Deferred Tax Liabilities Management Fees DeferredTaxLiabilitiesManagementFees	0	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2033000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3734000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	371000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1613000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	29000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14719000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5451000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9268000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3597000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14719000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1903000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1903000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1804000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	99000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1903000	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73249042	shares
CY2021Q4	toi	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	591
CY2021	toi	Common Stock Votes Per Share CommonStockVotesPerShare	1	vote
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	163510	shares
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	100	shares
CY2021Q4	toi	Class Of Warrant Or Right Threshold Number Of Business Days Before Sending Notice Of Redemption To Warrant Holders ClassOfWarrantOrRightThresholdNumberOfBusinessDaysBeforeSendingNoticeOfRedemptionToWarrantHolders	3	D
CY2018Q3	toi	Common Stock And Preferred Stock Shares Authorized CommonStockAndPreferredStockSharesAuthorized	30000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000	shares
CY2020Q4	toi	Common Stock And Preferred Stock Shares Authorized CommonStockAndPreferredStockSharesAuthorized	420000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000	shares
CY2020Q4	toi	Number Of Option Holders NumberOfOptionHolders	1	option_holder
CY2021Q1	toi	Number Of Accredited Investors NumberOfAccreditedInvestors	3	investor
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber	3724	shares
CY2020Q4	us-gaap	Goodwill Goodwill	14227000	USD
CY2021	toi	Number Of Rental Agreements For Property NumberOfRentalAgreementsForProperty	56	rental_agreement
CY2021	toi	Number Of Rental Agreements For Medical Equipment Classified As Capital Leases NumberOfRentalAgreementsForMedicalEquipmentClassifiedAsCapitalLeases	4	rental_agreement
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	37000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4263000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	37000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3946000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3291000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2718000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1954000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1044000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	103000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	17216000	USD
CY2021Q4	us-gaap	Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate	0.06
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	7000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	96000	USD
CY2021Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	33000	USD
CY2021Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	63000	USD
CY2021	us-gaap	Loss Contingency Accrual Payments LossContingencyAccrualPayments	350000	USD
CY2021	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	5	business_combination
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021	toi	Number Of Asset Acquired NumberOfAssetAcquired	1	asset_acquisition
CY2021Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.00
CY2021Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	275000000	USD
CY2021Q4	toi	Reverse Recapitalization Net ReverseRecapitalizationNet	762052000	USD
CY2021Q4	toi	Reverse Recapitalization Equity Consideration Value ReverseRecapitalizationEquityConsiderationValue	595468000	USD
CY2021Q4	toi	Reverse Recapitalization Equity Consideration Shares ReverseRecapitalizationEquityConsiderationShares	51300000	shares
CY2021Q4	toi	Reverse Recapitalization Equity Consideration Share Price ReverseRecapitalizationEquityConsiderationSharePrice	10.00
CY2021Q4	toi	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	166584000	USD
CY2021	toi	Proceeds From Reverse Recapitalization Transaction ProceedsFromReverseRecapitalizationTransaction	333946000	USD
CY2021	toi	Payments As A Result Of Recapitalization Transaction PaymentsAsAResultOfRecapitalizationTransaction	167510000	USD
CY2021Q4	toi	Reverse Recapitalization Expenses ReverseRecapitalizationExpenses	39914000	USD
CY2021Q4	toi	Accrued Reverse Recapitalization Costs AccruedReverseRecapitalizationCosts	6769000	USD
CY2021Q4	toi	Common Stock Votes Per Share CommonStockVotesPerShare	1	vote
CY2021Q4	toi	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	591
CY2021Q4	toi	Adjustments To Additional Paid In Capital Reverse Recapitalization AdjustmentsToAdditionalPaidInCapitalReverseRecapitalization	142557000	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	3023000	USD
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-1454000	USD
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	476000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	202316000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12195000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	26479000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8234000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18245000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	25234000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5718000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	19516000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2684000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2639000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2639000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2639000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2617000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	5027000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18245000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2516000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2487000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	26626000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	14227000	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	14227000	USD
CY2019Q4	us-gaap	Goodwill Gross GoodwillGross	14077000	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	12399000	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	150000	USD
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2020Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2021Q4	us-gaap	Goodwill Goodwill	26626000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-10927000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-14322000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66230606	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66230606	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59117723	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59117723	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-45858000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-8197000	USD
CY2021Q4	us-gaap	Assets Assets	203439000	USD
CY2020Q4	us-gaap	Assets Assets	65689000	USD
CY2021	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	744000	USD
CY2020	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	641000	USD

Files In Submission

Name	View Source	Status
0001628280-22-005868-index-headers.html	Edgar Link	pending
0001628280-22-005868-index.html	Edgar Link	pending
0001628280-22-005868.txt	Edgar Link	pending
0001628280-22-005868-xbrl.zip	Edgar Link	pending
exhibit231-consentofbdousa.htm	Edgar Link	pending
exhibit311-certificationpu.htm	Edgar Link	pending
exhibit312-certificationpu.htm	Edgar Link	pending
exhibit321-certificationpu.htm	Edgar Link	pending
exhibit322-certificationpu.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
toi-20211231.htm	Edgar Link	pending
toi-20211231.xsd	Edgar Link	pending
toi-20211231_cal.xml	Edgar Link	unprocessable
toi-20211231_def.xml	Edgar Link	unprocessable
toi-20211231_g1.jpg	Edgar Link	pending
toi-20211231_htm.xml	Edgar Link	completed
toi-20211231_lab.xml	Edgar Link	unprocessable
toi-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOI
Oncology Institute, Inc. Stock $toi

2021 Q4 Form 10-K Financial Statement

#000162828022005868 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOI Oncology Institute, Inc. Stock $toi

2021 Q4 Form 10-K Financial Statement

#000162828022005868 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOI
Oncology Institute, Inc. Stock $toi